ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03459469
Recruitment Status : Not yet recruiting
First Posted : March 9, 2018
Last Update Posted : March 12, 2018
Sponsor:
Information provided by (Responsible Party):
Beta Cat Pharmaceuticals, Inc.

March 1, 2018
March 9, 2018
March 12, 2018
March 15, 2018
September 1, 2019   (Final data collection date for primary outcome measure)
To evaluate the safety and tolerability [ Time Frame: 12 Months ]
Adverse events, Serious adverse events and Dose limiting toxicities
Same as current
Complete list of historical versions of study NCT03459469 on ClinicalTrials.gov Archive Site
1. To determine the durability of response (DOR) to BC2059 after the achievement of best response [ Time Frame: 12 Months ]
Assessing CR and PR
Same as current
Not Provided
Not Provided
 
Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Phase I, open-label, non-randomized study to evaluate safety of BC2059 administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive.
This study is a phase I, open-label, non-randomized study to evaluate safety of BC2059 administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive. This study will utilize single patient cohorts for the first two dose levels in order to minimize sub-optimal drug exposures, followed by a conventional 3+3 dose escalation phase to achieve MTD or RP2D determined by pharmacokinetics or biologically relevant activity. Once MTD or RP2D is determined, that dose level cohort will expand to 14 patients enrolled to collect additional safety PK and PD data. If at least 1 patient has clinical benefit, the dose expansion phase will be expanded by a further 11 patients (25 total in at RP2D). The total duration of study for each subject will be dependent upon the safety, tolerability and efficacy of BC2059
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Desmoid Tumor
Drug: Tegavivint
This is an Investigational drug
Other Name: BC2059
Experimental: Investigational drug
An open-label, non-randomized study to evaluate safety of Tegavivint administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive.
Intervention: Drug: Tegavivint
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
25
Same as current
November 1, 2019
September 1, 2019   (Final data collection date for primary outcome measure)

Inclusion criteria

  • Patients with histologically proven primary or recurrent desmoid tumor with currently bi-dimensionally measurable tumor by WHO criteria.
  • Patients with disease that is either unresectable or for which the patient refuses surgery but is currently progressing, as defined by:

    • 20% increase in tumor volume within 6 months OR
    • Recurrent disease within 1 year of surgery OR
    • Desmoid related symptoms as documented by a PRO questionnaire and documentation that symptoms are related to desmoid and not prior therapies.
  • Willingness to provide tumor biopsies prior to treatment and while on treatment
  • Patients may have been previously treated with local therapies such as surgery, radiation, radiofrequency ablation, or cryosurgery provided this has been completed at least 4 weeks prior to registration and recovered from therapy related toxicity to less than CTCAE grade 2 and show no improvement in tumor size or symptom score.
  • Patients may have been treated with systemic therapies such as tyrosine kinase inhibitors, hormone inhibitors or nonsteroidal anti-inflammatory drugs (NSAIDs) provided this has been completed at least 4 weeks prior to registration and recovered from any therapy related toxicity to less than CTCAE grade 2 and show no improvement in tumor size or symptom score.
  • Patients may have been treated with systemic therapies such as cytotoxics, biologics or other unclassified experimental therapies provided this has been completed at least 8 weeks prior to registration and recovered from any therapy related toxicity to less than CTCAE grade 2 and show no improvement in tumor size or symptom score.
  • Patients who have been treated with immune therapies such as vaccines, dendritic or other whole cell therapies, oncolytic or other viral approaches within the preceding 12 months should be discussed with the Medical Monitor prior to screening and enrollment into the study to determine eligibility.
  • Age: 18 and over (no pre-pubertal patients)
  • ECOG Performance status: 0-1
  • Hematopoietic:

    • Absolute granulocyte count ≥ 1,500/mm3
    • Platelet count ≥ 100,000/mm3
    • Hemoglobin at least 10.0 g/dL (transfusion allowed)
  • Hepatic:

    • Bilirubin no greater than 1.5 times institutional upper limit of normal, in the absence of documented Gilbert's syndrome
    • Transaminases no greater than 3 times upper limit of normal (ULN)
    • Alkaline phosphatase no greater than 3 times ULN
  • Renal: Creatinine clearance ≥75 mL/min by Cockcroft-Gault
  • Pulmonary:

    • Diffusing capacity of the lung for carbon monoxide (DLCO) greater than 75% predicted by single breath test
    • Capillary oxygen saturation (O2 sat) > 95% by pulse oximetry

Exclusion Criteria

  • Patients who have not recovered to grade 1 from adverse events related to prior therapy excluding those considered not clinically significant (ex. Lymphopenia).
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to BC2059 or other agents used in study
  • Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
  • Uncontrolled concurrent illness including, but not limited to: ongoing or active infection (Viral, bacterial, fungal or other)
  • Psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant and breastfeeding women are excluded from this study. The effects of BC2059 on the developing human fetus have the potential for teratogenic or abortifacient effects. There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BC2059.
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of BC2059 administration.
  • HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with BC2059
  • Patients with abnormal serum chemistry values other than the specific limits detailed above, that in the opinion of the Investigator is considered to be clinically significant, should be discussed with the Medical Monitor before being enrolled in the study.
  • Lack of peripheral venous or central venous access or any condition that would interfere with drug administration or collection of study samples
  • Personal history of malignancy except:

    • Cervical intraepithelial neoplasia;
    • Skin basal cell carcinoma;
    • Treated localized prostate carcinoma with PSA <1 ng/mL;
    • Neoplasia treated with curative intent, in remission for at least five years and considered at low risk of relapse.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Not Provided
 
 
NCT03459469
BCI-001-DT17
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Beta Cat Pharmaceuticals, Inc.
Beta Cat Pharmaceuticals, Inc.
Not Provided
Not Provided
Beta Cat Pharmaceuticals, Inc.
December 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP